Analytical Data
-
Gene name
MYH14
- Application
-
Alternative Names
DFNA4; NMHC-II-C; MHC16; MYH17
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q7Z406
-
Expression Region
Arg1069~Leu1331
-
Molecular Weight
34kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MYH14, a member of the myosin heavy chain family, plays a vital role in various cellular processes, including muscle contraction, cellular motility, and intracellular transport. This protein is particularly significant in the context of smooth muscle function and is implicated in several physiological and pathological conditions. Recent studies have highlighted the importance of MYH14 in regulating cellular activities, such as cell adhesion and migration, which are crucial for tissue development and repair. Abnormalities in MYH14 expression or function have been associated with diseases, including cancer and cardiovascular disorders, making it a potential biomarker for diagnostic and therapeutic purposes. The recombinant MYH14 protein, produced through recombinant DNA technology, offers an opportunity for in-depth studies into its structure-function relationships, interactions with other proteins, and potential roles in disease mechanisms. By utilizing recombinant MYH14, researchers aim to elucidate the intricate pathways in which this protein is involved, paving the way for innovative therapeutic strategies targeting MYH14-related diseases. The development of MYH14 recombinant protein presents a promising avenue to further explore the biological significance of this myosin in both health and disease, contributing to our understanding of muscle physiology and targeted treatment approaches.
